Last10K.com

Conduit Pharmaceuticals Inc. (CDT) SEC Filing 10-Q Quarterly Report for the period ending Saturday, September 30, 2023

Conduit Pharmaceuticals Inc.

HISTORY TOOLS
CIK: 1896212 Ticker: CDT
Cover - shares
9 Months Ended
Sep. 30, 2023
Nov. 20, 2023
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateSep. 30, 2023 
Document Fiscal Period FocusQ3 
Document Fiscal Year Focus2023 
Current Fiscal Year End Date--12-31 
Entity File Number001-41245 
Entity Registrant NameCONDUITPHARMACEUTICALS INC. 
Entity Central Index Key0001896212 
Entity Tax Identification Number87-3272543 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One4995 Murphy Canyon Road 
Entity Address, Address Line TwoSuite 300 
Entity Address, City or TownSan Diego 
Entity Address, State or ProvinceCA 
Entity Address, Postal Zip Code92123 
City Area Code(760) 
Local Phone Number471-8536 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companytrue 
Elected Not To Use the Extended Transition Periodfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 72,813,776
Common Stock, par value $0.0001 per share  
Title of 12(b) SecurityCommon Stock, par value $0.0001 per share 
Trading SymbolCDT 
Security Exchange NameNASDAQ 
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50  
Title of 12(b) SecurityRedeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 
Trading SymbolCDTTW 
Security Exchange NameNASDAQ 

View differences made from one quarter to another to evaluate Conduit Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Conduit Pharmaceuticals Inc..

Continue

Assess how Conduit Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Conduit Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited)
Condensed Consolidated Statements Of Operations And Comprehensive Income (Loss) (Unaudited)
Balance Sheet Details ??? Current Assets And Current Liabilities
Balance Sheet Details ??? Current Assets And Current Liabilities (Tables)
Commitments And Contingencies
Common Stock And Preferred Stock
Common Stock And Preferred Stock (Details Narrative)
Convertible Notes Payable
Convertible Notes Payable (Details Narrative)
Deferred Commission Payable
Deferred Commission Payable (Details Narrative)
Earnings/(Net Loss) Per Share Attributable To Common Stockholders
Earnings/(Net Loss) Per Share Attributable To Common Stockholders (Tables)
Fair Value
Fair Value (Details Narrative)
Fair Value (Tables)
Income Taxes
Income Taxes (Details Narrative)
Liability Related To The Sale Of Future Revenue
Liability Related To The Sale Of Future Revenue (Details Narrative)
Liability Related To The Sale Of Future Revenue (Tables)
Loans Payable
Loans Payable (Details Narrative)
Merger
Merger (Details Narrative)
Merger (Tables)
Nature Of The Business, Basis Of Presentation And Summary Of Significant Accounting Policies
Nature Of The Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Details Narrative)
Nature Of The Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Other Income (Expense), Net
Other Income (Expense), Net (Tables)
Related Party Transactions
Related Party Transactions (Details Narrative)
Revision Of Previously Issued Financials
Revision Of Previously Issued Financials (Tables)
Schedule Of Accounts Payable, Accrued Expenses And Other Current Liabilities (Details)
Schedule Of Additional Information About The Financial Liabilities Subject To Measurement At Fair Value (Details)
Schedule Of Additional Information About The Financial Liabilities Subject To Measurement At Fair Value (Details) (Parenthetical)
Schedule Of Additional Information About The Option Liability Subject To Measurement At Fair Value (Details)
Schedule Of Balance Sheet Details (Details)
Schedule Of Basic And Diluted Net Loss Per Share (Details)
Schedule Of Common Stock Outstanding (Details)
Schedule Of Fair Value Significant Unobservable Inputs (Details)
Schedule Of Impact Of The Errors On Financial Statement (Details)
Schedule Of Liabilities Subject To Measurement At Fair Value On Recurring Basis (Details)
Schedule Of Liability For The Sale Of Future Revenue (Details)
Schedule Of Other Expense, Net (Details)
Schedule Of Potentially Dilutive Securities (Details)
Share Based Compensation
Share Based Compensation (Details Narrative)
Subsequent Events
Warrant Liability
Warrant Liability (Details Narrative)

Material Contracts, Statements, Certifications & more

Conduit Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: CDT
CIK: 1896212
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-23-042176
Submitted to the SEC: Mon Nov 20 2023 5:29:50 PM EST
Accepted by the SEC: Mon Nov 20 2023
Period: Saturday, September 30, 2023
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/cdt/0001493152-23-042176.htm